Ahmad Aziz
Population & Clinical Neuroepidemiology
Dr. Dr. Ahmad Aziz
Career Development Fellow
Venusberg-Campus 1/99
53127  Bonn

ahmad.aziz@dzne.de
 +49 228 43302-954

Areas of investigation/research focus

Using deep (endo)phenotypic data obtained in the context of both population-based and clinical cohort studies, we aim to identify the risk factors, causes as well as trait and state markers of neurodegenerative diseases through application of epidemiological and bio-informatics approaches. Currently, the focus of my group is on the following three projects:

Tandem repeat variations as modifiers of brain structure and function.

Until recently it was assumed that genomic tandem repeat variations are only relevant for human health when mutated into extremely large expansions, causing several hereditary neurodegenerative diseases like Huntington disease and several spinocerebellar ataxias. However, we recently found that 1) polyglutamine disease-associated alleles with intermediate or pathological range cytosine-adenine-guanine (CAG) repeat lengths are much more prevalent in the general population than previously thought, 2) even CAG repeat variations in the normal range can act as modifiers of cognitive function, depression risk and body weight in the general population, and 3) in patients with neurodegenerative conditions like Huntington disease, Parkinson disease and Alzheimer disease, DNA repeat variations can modify disease characteristics such as age-of-onset and severity of symptoms. To identify novel genetic risk factors and causal mechanisms involved in the pathogenesis of neurodegenerative diseases, currently we are investigating the relation between a large number of tandem repeat-containing genomic loci and detailed (MR imaging-based) measures of brain structure, connectivity and function in the general population.

 more Infos

Elucidation of the neuroanatomical basis of motor function across lifespan.

Deterioration of motor function is an early feature of many neurodegenerative diseases, whereas physical activity may protect against neurodegeneration and cognitive decline. Elucidating the neuroanatomical basis of motor dysfunction across lifespan is thus crucial for both identification of early markers of, and development of more effective preventive and therapeutic strategies against, neurodegenerative diseases. Therefore, here we aim to assess the relation between accelerometer-based physical activity, as well as inertial motion sensor-based whole-body motor performance, with structural integrity and connectivity of relevant brain regions across lifespan in the population-based Rhineland Study.

Hypothalamic dysfunction as a driver of age-related cognitive decline.

The hypothalamus is the body’s principal homeostatic center and plays a crucial role in the modulation of cognition. However, whether hypothalamic pathology could be a risk factor for or marker of cognitive decline has not been studied in the general population for lack of a scalable high-throughput analysis method. Therefore, in this project we are developing a novel automated parcellation procedure to accurately delineate hypothalamic structures on MR images, and aiming to apply this method to relate various measures of hypothalamic structural and functional integrity to cognitive function in the population-based Rhineland Study.

Key publications

Gardiner SL, Boogaard MW, Trompet S, de Mutsert R, Rosendaal FR, Gussekloo J, Jukema JW, Roos RA, Aziz NA. High prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles in large population-based cohorts. JAMA Neurol. 2019 Jan 01; 76:650-656. doi: 10.1001/jamaneurol.2019.0423
Gardiner SL, Harder AV, Campman YJ, Trompet S, Gussekloo J, Van Belzen MJ, Boogaard MW, Roos RA, Jansen IE, Pijnenburg YA, Scheltens Ph, Van der Flier WM, Aziz NA. Repeat length variations in polyglutamine disease-associated genes modify disease expression in Alzheimer disease. Neurobiol Aging. 2019 Jan 01; 73:230.e9-17. doi: 10.1016/j.neurobiolaging.2018.09.007
Aziz NA, Van der Burg JM, Tabrizi SJ, Landwehrmeyer GB. Overlap between age of onset and progression determinants in Huntington disease. Neurology. 2018 Jan 01; 90:2099-2106. doi: 10.1212/WNL.0000000000005690
Van der Burg JM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RA, Aziz NA. Body weight is a robust predictor of clinical progression in Huntington disease. Annals of Neurology. 2017 Jan 01; 82:479-483. doi: 10.1002/ana.25007
Aziz NA, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group; Roos RA. Weight loss in Huntington’s disease increases with higher CAG repeat number. Neurology. 2008 Jan 01; 71:1506-1513. doi: 10.1212/01.wnl.0000334276.09729.0e

Info-Hotline

Thursdays 1:30-4:30 pm

Patients +49 800-7799001

(free of charge)

Professionals +49 180-779900

(9 Cent/Min. German landline, mobile and out of Germany possibly more expensive)

Welcome to our website, here you can inform yourself basically cookie-free.

We would be pleased if you would allow a cookie to be set for analysis purposes in order to optimise our provided information. All data are pseudonymous and are only used by the DZNE. We deliberately avoid third-party cookies. You can deselect this setting at any time here.

Your browser allows the setting of cookies: